Isolation of a novel neutralizing antibody fragment against human vascular endothelial growth factor from a phage-displayed human antibody repertoire using an epitope disturbing strategy

Journal of Biotechnology

Volumn 151, Issue 2, 2011, Pages 166-174

  Lamdan, Humberto ^a   Ayala, Marta ^a   Rojas, Gertrudis ^a,b   Munoz, Yasmiana ^a   Morera, Yanelys ^a   Guirola, Osmany ^a   Chinea, Glay ^a   Gavilondo, Jorge V ^a  

^a CENTER FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Cuba)

^b CENTER OF MOLECULAR IMMUNOLOGY   (Cuba)

Author keywords

Angiogenesis; Epitope disturbing; Neutralizing antibody; Phage display; VEGF

Indexed keywords

ANGIOGENESIS; EPITOPE DISTURBING; NEUTRALIZING ANTIBODIES; PHAGE DISPLAY; VEGF;

BINDING ENERGY; CHEMICAL MODIFICATION; ECOLOGY; ENDOTHELIAL CELLS; MONOCLONAL ANTIBODIES; PEPTIDES; SELF ASSEMBLY;

ANTIGENS;

BEVACIZUMAB; EPITOPE; NEUTRALIZING ANTIBODY; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

ARTICLE; CELL PROLIFERATION; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VIVO STUDY; MOLECULAR CLONING; NONHUMAN; PRIORITY JOURNAL; UMBILICAL VEIN ENDOTHELIAL CELL;

ANTIBODIES; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; ANTIGENS; ENDOTHELIAL CELLS; EPITOPES; HUMANS; IMMUNOGLOBULIN FRAGMENTS; MUTATION; NEOVASCULARIZATION, PHYSIOLOGIC; PEPTIDE LIBRARY; UMBILICAL VEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 78651499207     PISSN: 01681656     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbiotec.2010.12.007     Document Type: Article

References (36)

1. Alonso R., Huerta V., de Leon J., Piedra P., Puchades Y., Guirola O., Chinea G., Montero E. Towards the definition of a chimpanzee and human conserved CD6 domain 1 epitope recognized by T1 monoclonal antibody. Hybridoma 2008, 27:291-301.
2. Bonner J.A., Harari P.M., Giralt J., Azarnia N., Shin D.M., Cohen R.B., Jones C.U., Sur R., Raben D., Jassem J., Ove R., Kies M.S., Baselga J., Youssoufian H., Amellal N., Rowinsky E.K., Ang K.K. Radiotherapy plus Cetuximab for squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 2006, 354:567-578.
3. Brekken R.A., Overholser J.P., Stastny V.A., Waltenberger J., Minna J.D., Thorpe P.E. Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice. Cancer Res. 2000, 60:5117-5124.
4. Crombet T., Osorio M., Cruz T., Roca C., del Castillo R., Mon R., Iznaga-Escobar N., Figueredo R., Koropatnick J., Renginfo E., Fernández E., Alvárez D., Torres O., Ramos M., Leonard I., Pérez R., Lage A. Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients. J. Clin. Oncol. 2004, 22:1646-1654.
5. Ditzel H.J., Binley J.M., Moore J.P., Sodroski J., Sullivan N., Sawyer L.S.W., Hendry R.M., Yang W., Barbas Ill C.F., Burton D.R. Neutralizing recombinant human antibodies to a conformational V2- and CD4-binding site-sensitive epitope of HIV-1 gp120 isolated by using an epitope-masking procedure. J. Immunol. 1995, 154:893-906.
6. Enshell-Seijffers D., Denisov D., Groisman B., Smelyanski L., Meyuhas R., Gross G., Denisova G., Gershoni J.M. The mapping and reconstitution of a conformational discontinuous B-cell epitope of HIV-1. J. Mol. Biol. 2003, 334:87-101.
7. Felici F., Castagnoli L., Musacchio A., Jappelli R., Cesareni G. Selection of antibody ligands from a large library of oligopeptides expressed on a multivalent exposition vector. J. Mol. Biol. 1991, 222:301-310.
8. Ferrara N. Vascular endothelial growth factor as a target for anticancer therapy. Oncologist 2004, 9:2-10.
9. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med. 1995, 1:27-31.
10. Folkman J. Angiogenesis: an organizing principle for drug discovery? Nat. Rev. Drug Discov. 2007, 6:273-286.
11. Fuh G., Wu P., Liang W.C., Ultsch M., Lee C.V., Moffat B., Wiesmann C. Structure-function studies of two synthetic anti-vascular endothelial growth factor Fabs and comparison with the AvastinTM Fab. J. Biol. Chem. 2006, 281:6625-6631.
12. Huang J., Gutteridge A., Honda W., Kanehisa M. MIMOX: a web tool for phage display based epitope mapping. BMC Bioinformatics 2006, 7:451.
13. Hurwitz H., Fehrenbacher L., Novotny W., Cartwright T., Hainsworth J., Heim W., Berlin J., Baron A., Griffing S., Holmgren E., Ferrara N., Fyfe G., Rogers B., Ross R., Kabbinavar F. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 2004, 350:2335-2342.
14. Jaffe E.A., Nachman R.L., Becker C.G., Minick R. Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. J. Clin. Invest. 1973, 52:2745-2756.
15. Keyt B.A., Nguyen H.V., Berlau L.T., Duartes C.M., Park J., Chen H., Ferrara N. Identification of vascular endothelial growth factor determinants for binding KDR and FLT-1 receptors. J. Biol. Chem. 1996, 271:5638-5646.
16. Koch A.E., Harlow L.A., Haines G.K., Amento E.P., Unemori E.N., Wong W.L., Pope R.M., Ferrara N. Vascular endothelial growth factor. A cytokine modulating endothelial function in rheumatoid arthritis. J. Immunol. 1994, 152:4149-4156.
17. Liang W.C., Wu X., Peale F.V., Lee C.V., Meng Y.G., Gutierrez J., Fu L., Malik A.K., Gerber H.P., Ferrara N., Fuh G. Cross-species vascular endothelial growth factor (VEGF)-blocking antibodies completely inhibit the growth of human tumor xenografts and measure the contribution of stromal VEGF. J. Biol. Chem. 2006, 281:951-961.
18. Marks J.D., Hoogenboom H.R., Bonnerta T.P., McCafferty J., Griffiths A.D., Winter G. By-passing immunization-human antibodies from V-gene libraries displayed on phage. J. Mol. Biol. 1991, 222:581-597.
19. Morera Y., Bequet-Romero M., Ayala M., Lamdan H., Agger E.M., Andersen P., Gavilondo J.V. Anti-tumoral effect of active immunotherapy in C57BL/6 mice using a recombinant human VEGF protein as antigen and three chemically unrelated adjuvants. Angiogenesis 2008, 11:381-393.
20. Morera Y., Bequet-Romero M., Ayala M., Castro J., Puentes P., Suárez J., Ancizar J., Rodríguez M., Cosme K., Gavilondo J.V. Immunogenicity and some safety features of a VEGF-based cancer therapeutic vaccine in rats, rabbits and non-human primates. Vaccine 2010, 28:3453-3461.
21. Muller Y.A., Christinger H.W., Keyt B.A., de Vos A.M. The crystal structure of vascular endothelial growth factor (VEGF) refined to 1.93Å resolution: multiple copy flexibility and receptor binding. Structure 1997, 5:1325-1338.
22. Muller Y.A., Chen Y., Christinger H.W., Li B., Cunningham B.C., Lowman H.B., de Vos A.M. VEGF and the Fab fragment of a humanized neutralizing antibody: crystal structure of the complex at 2.4Å resolution and mutational analysis of the interface. Structure 1998, 6:1153-1167.
23. Parsons H.L., Earnshaw J.C., Wilton J., Johnson K.S., Schueler P.A., Mahoney W., McCafferty J. Directing phage selections towards specific epitopes. Protein Eng. 1996, 9:1043-1049.
24. Pavlik P., Siegel R.W., Marzari R., Sblattero D., Verzillo V., Collins C., Marks J.D., Bradbury A. Predicting antigenic peptides suitable for the selection of phage antibodies. Hum. Antibodies 2003, 12:99-112.
25. Perez L., Ayala M., Pimentel G., Bell H., Cannan-Haden L., Bequet M., Gonzalez L., Miranda M., Ravelo R., Roque L., Acevedo B., Oliva J., Gavilondo J.V. A multivalent recombinant antibody fragment specific for carcinoembryonic antigen. Biotechnol. Appl. Biochem. 2006, 43:39-48.
26. Presta L.G., Chen H., O'Connor S.J., Chisholm V., Meng Y.G., Krummen L., Winkler M., Ferrara N. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 1997, 57:4593-4599.
27. Rojas G., Lamdan H., Padron S., Munoz Y., Ayala M., Gavilondo J.V. Efficient construction of a highly useful phage-displayed human antibody repertoire. Biochem. Biophys. Res. Commun. 2005, 336:1207-1213.
28. Roland C.L., Dineen S.P., Lynn K.D., Sullivan L.A., Dellinger M.T., Sadegh L., Sullivan J.P., Shames D.S., Brekken R.A. Inhibition of vascular endothelial growth factor reduces angiogenesis and modulates immune cell infiltration of orthotopic breast cancer xenografts. Mol. Cancer Ther. 2009, 8:1761-1771.
29. Shen B.Q., Lee D.Y., Gerber H.P., Keyt B.A., Ferrara N., Zioncheck T.F. Homologous up-regulation of KDR/Flk-1 receptor expression by vascular endothelial growth factor in vitro. J. Biol. Chem. 1998, 273:29979-29985.
30. Shibuya M., Yamaguchi S., Yamane A., Ikeda T., Tojo A., Matsushime H., Sato M. Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase (flt) closely related to the fms family. Oncogene 1990, 5:519-524.
31. Steiner D., Forrer P., Plückthun A. Efficient selection of DARPins with sub-nanomolar affinities using SRP phage display. J. Mol. Biol. 2008, 382:1211-1227.
32. Talavera A., Friemann R., Gómez-Puerta S., Martinez-Fleites C., Garrido G., Rabasa A., López-Requena A., Pupo A., Johansen R.F., Sánchez O., Krengel U., Moreno E. Nimotuzumab, an antitumor antibody that targets the epidermal growth factor receptor, blocks ligand binding while permitting the active receptor conformation. Cancer Res. 2009, 69:5851-5859.
33. Tarnovitski N., Matthews L.J., Sui J., Gershoni J.M., Marasco W.A. Mapping a neutralizing epitope on the SARS coronavirus spike protein: computational prediction based on affinity-selected peptides. J. Mol. Biol. 2006, 359:190-201.
34. Terman B.I., Dougher-Vermazen M., Carrion M.E., Dimitrov D., Armellino D.C., Gospodarowicz D., Bohlen P. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. Biochem. Biophys. Res. Commun. 1992, 187:1579-1586.
35. Tsui P., Tornetta M.A., Ames R.S., Bankosky B.C., Griego S., Silverman C., Porter T., Moore G., Sweet R.W. Isolation of a neutralizing human RSV antibody from adominant, non-neutralizing immune repertoire by epitope-blocked panning. J. Immunol. 1996, 157:772-780.
36. Witmer A.N., Vrensen G.F.J.M., Van Noorden C.J.F., Schlingemann R.O. Vascular endothelial growth factors and angiogenesis in eye disease. Prog. Retinal Eye Res. 2003, 22:1-29.